Utilizing EMR capabilities to improve shared decision-making regarding DPYD pharmacogenomic testing. Comparison of medication verification and restart times before and after SOP-based intervention.
Phase Ib Study of BI 836880 (VEGF/Ang2 nanobody) in Combination With Ezabenlimab (anti–PD-1 antibody) in Patients With Advanced or Metastatic Solid Tumors From December 2022 to January 2025, one MRT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results